Teva's Fingerprints on Reviva

🌾 Welcome to StableBread's Newsletter!

The next time you find yourself on EDGAR, consider using my SECSift reader instead!

It turns SEC filings into clean, readable documents. You can search every word, export anything, merge tables, highlight what matters and gray out the rest, and compare against previous filings.

Here’s a 3-minute interactive demo (viewable on your computer) and video I made walking through the entire tool.

Annual plans (for more AI usage, extra storage, merging tables, exporting) are 25% off with code “SB25” through August 31.

I wrote up Reviva Pharmaceuticals (OTCQB: RVPH) on June 18 at $0.63/share.

The thesis was that you were buying a broken-looking biotech wrapped around a credible, late-stage schizophrenia drug, for less than the cash on its books.

Reviva's Phase 3 schizophrenia drug, brilaroxazine, has already cleared two efficacy trials and a year-long safety extension (a 52-week open-label study completed in 2025) across ~900 patients.

On the company's own comparisons, its trial data reads stronger than Caplyta's, the schizophrenia pill Johnson & Johnson (JNJ) paid $14.6B for in January 2025.

For brilaroxazine to reach the market, Reviva must run one more confirmatory Phase 3, called RECOVER-2 (which the FDA asked for in December 2025), and fund the $50-55M the trial and approval filing will cost.

Reviva reported Q2 earnings on August 12. The main takeaway is that the Phase 3 timeline, and the approval at the end of it, slipped again. RECOVER-2 was supposed to start enrolling this quarter and now starts in H1 2027, the FDA feedback needed before the trial starts moved from mid-2026 to Q4 2026, and the readout that decides FDA approval now lands in 2028.

RVPH stock is down ~27% since the write-up, and on the quarter alone, there's not much to discuss. The story is unchanged, just pushed out a year.

What makes Reviva worth a full write-up are two key developments:

Below, I'll recap brilaroxazine's timeline and the Q2 financials, discuss both developments in depth, and close with how I'm approaching the stock from here.

The original brilaroxazine patents expire in 2030. Reviva says the first US one "may be extendable up to 2035" if the drug is approved. That means an acquirer is buying only ~5 years of exclusivity.

That doesn't fund a label expansion into bipolar and depression. Nor does it make brilaroxazine an attractive acquisition target for big pharma.

The fix is the new form, a different drug substance and a different formulation, which is what Reviva is trying to patent separately.

The "new form" is the same brilaroxazine molecule built in a different physical form and formulation, not a new drug. Because the molecule is unchanged, Reviva expects the ~900 patients of existing trial data to carry over, with a short bridging study (a ~30-patient bioequivalence trial) to prove the new form behaves the same in the body.

A provisional application, the placeholder filing that reserves Reviva's priority date on the new form, has been in place since Q1. The bigger step came on August 11, when Reviva filed the full composition of matter application—the patent covering the new form of the molecule itself—internationally through PCT, and put the US version on the USPTO's Track One fast track.

Two caveats to know:

With that background, here's where the four catalysts I listed in June stand today:

So the Q4 2026 FDA feedback is the next date that matters. Bhat said in late June the package for the agency was still being put together, which explains the wait.

The dates below cover two separate tracks. The bioequivalence study, RECOVER-2, and the NDA all run through the FDA, in that order. The new-form patent runs through the USPTO, which grants patents and has no say on the drug.

Here’s what the current sequence looks like:

The 2046 patent runs on its own clock. RECOVER-2 can start before the USPTO grants the new-form patent, and the USPTO can grant the patent whether or not RECOVER-2 has started. What the trial requires first is the FDA's Q4 feedback, not the patent.

Reviva ended Q2 with $2.3M less cash than it had in Q1, yet now guides a longer runway. RECOVER-2 slipped to H1 2027, so the spending that would’ve started this year is deferred until enrollment begins.

Here's how the quarter itself reported:

The runway guide also implies Reviva expects its spending to roughly double. If $19.9M is gone by July 2027, the average burn must run ~$1.6M/month, double today's ~$0.8M/month pace, consistent with the bioequivalence study and RECOVER-2 spending ahead.

One call I had wrong in June was treating steady ATM dilution, sales of new shares directly into the market under Reviva's $50M ATM facility, as the base case. Reviva sold nothing under the ATM in Q2 "and through the filing date," and the Q2 10-Q says the company "does not expect to utilize" the facility while the stock is quoted on OTC Markets.

If we take management's word, steady dilution is paused for now. But that doesn’t mean the funding gap simply disappears. On an April fireside chat, Bhat put the cost of RECOVER-2 plus the NDA at $50-55M, so against $19.9M of cash the shortfall is $30-35M.

Even that understates the gap, because the same $19.9M is also covering ~$0.8M/month of ongoing outlays, plus the bioequivalence study, before enrollment starts.

The first place to look for that money is the warrants from Reviva's March 2026 offering, and they work against the timing:

At $0.46/share, the stock has to more than triple by March 2027 for that first $10M to unlock, in the same half-year enrollment is supposed to begin. If the stock doesn't get there, the money has to come from a collaboration that trades rights to the program for funding, or from a raise near the current price.

Notably, the market is still pricing liquidation. The stock is trading at $0.46/share, which translates to a $6.0M market cap against $19.9M of cash and $0.1M of debt, an enterprise value of roughly negative $14M.

In other words, each share carries $1.52 of cash and $1.16 of book value.

When I wrote it up at $0.63/share the stock traded at ~37% of cash. It's now ~30%, on a few thousand dollars of daily volume. So each dollar of Reviva's cash now costs 30 cents instead of 37 cents, while the wait got a year longer.

Zacks Small-Cap Research updated its coverage on August 17, and a few parts are worth passing along. Zacks SCR is research the company pays for, although the management access makes the information valuable.

Negative-Symptoms Angle

Zacks reports Reviva is exploring a second, closely related indication for brilaroxazine, meaning a separate FDA-approved use for the same drug.

The target is the negative symptoms of schizophrenia, the social withdrawal and blunted emotion current drugs barely touch, and Reviva is planning another trial focused on them (no exact date provided).

Negative symptoms are where brilaroxazine's trial results look strongest against other antipsychotics, confirmed by the vocal biomarker study published in Biological Psychiatry in January. A dedicated indication there would be a second lever on patent life and label value that hasn't appeared in any Reviva press release.

Dilution Model

Zacks carries the share count from 13.1M today to 21M in 2027 and 25.5M in 2028, with R&D stepping up to $22.1M next year.

Their full model is below (focus on the share count row):

If Reviva funds RECOVER-2 by selling stock at these prices, the share count roughly doubles (according to Zacks’ model). Management not expecting to use the ATM (per the Q2 10-Q) doesn't prevent this, since Reviva can still sell stock through regular offerings, as it did in March.

Zacks also read the runway more conservatively, estimating funds last to Q1 2027 against Reviva's "into July 2027."

Valuation

Zacks' DCF lands at $5.00/share, built on a 15% discount rate, a 60% probability brilaroxazine gets approved, and commercialization starting in 2030.

You don't really need a DCF model for Reviva given the stock trades at ~30% of cash and the bet is on discrete events: (1) the FDA feedback, (2) the patent decision, (3) the financing, and eventually (4) the RECOVER-2 readout.

Regardless, commercialization in 2030 matches our timeline, and Zacks' DCF model considers two important risks: (1) a 40% chance of failure and (2) a roughly doubled share count. Even then, Zacks implies RVPH would be ~10x above today's price.

DTM5 is where I originally came across Reviva. You should definitely check out his research and subscribe to his Substack!

On August 14, he posted yet another Reviva write-up called “A Monster In The Deep” (read his work first).

In June, I wrote that a partner or acquirer funding the program was one of Reviva's two paths forward, but I couldn't name who that might be. DTM's research names a candidate.

His finding is that Teva (NYSE: TEVA), through Assia Chemical Industries (the arm of Teva that makes active pharmaceutical ingredients), has run a deep solid-state program on brilaroxazine. Assia has been mapping the crystalline forms and salts the molecule can take, how to make them, and how they hold up under heat, humidity, grinding, and compression.

I pulled the document itself, WO2024147096A1 ("Solid state forms of brilaroxazine and brilaroxazine salts"), with Assia Chemical Industries Ltd. as the applicant, and the application already moved into the patent offices of Europe, Japan, and China.

Assia's earliest filing date, the January 7, 2023 priority date highlighted in the image above, came nine months before Reviva announced positive Phase 3 results from RECOVER in October 2023.

In other words, somebody at Teva decided brilaroxazine was worth patent spending before knowing whether the drug's Phase 3 would succeed.

Assia's application even shows up in the "Cited By" table on Reviva's original composition patent, where every other citation is Reviva or its founder:

DTM pulled every third-party compound he could find with the same two markers, meaning an Assia filing on the compound's crystal forms plus a successful Phase 3.

He counted 18. Of those, 12 are FDA-approved, 5 remain in late-stage development, and 1 clearly failed, with several of the developers acquired along the way:

DTM's base rate depends on that list being right, so I checked all 18 compounds myself, and it holds up. The one caveat is daprodustat, which was approved but GSK pulled it off the US market in December 2024 for "business reasons" (it stays on sale in Japan as Duvroq).

The same search pattern also surfaces at least a dozen more Teva-studied compounds with successful Phase 3 trials, resmetirom, danicopan, fezolinetant, and ripretinib among them, and most of those also ended in FDA approvals.

So if anything, there's a bigger sample with the same lopsided outcome.

The precedent that matters most is Emalex Biosciences. Assia studied and patented ecopipam before its Phase 3 succeeded, and Teva then bought Emalex for $700M upfront plus up to $200M in milestones.

The deal closed June 10 under Teva's "Pivot to Growth" strategy, which has the company building a neuroscience franchise around UZEDY, its long-acting schizophrenia injectable. Teva filed the ecopipam NDA after closing, and the FDA accepted it with priority review on August 19.

Emalex also isn't the first time Teva studied a company's molecules before buying the company. Teva filed crystalline-form applications on Cephalon's modafinil as far back as 2000 and on armodafinil in 2006, ~5-11 years before it acquired Cephalon for $6.8B in 2011.

The motive was different there, though. Modafinil had been on the market since 1998, and Teva was one of the generic makers trying to sell copies of it (per the FTC), so those filings were generic-drug prep, not scouting an unapproved molecule.

DTM's post also mentions a “derivation proceeding,” a patent-office case that decides who actually invented a claimed invention. Reviva actually disclosed this proceeding itself in the 10-K it filed in March:

So an unnamed third party filed a US application claiming a form of brilaroxazine, and Reviva went to the patent board arguing the invention came from its own work.

DTM infers Teva is that party. He can't prove it and labels it an inference, but Assia's filings are the only significant third-party patents on brilaroxazine forms he could find (I couldn't identify any either), and the timing and subject matter line up.

Now, you may consider "Teva patenting Reviva's drug" a threat, but I don't consider it one.

Reviva owns the composition of matter patent on the molecule itself, granted in the US, Europe, and over a dozen other countries. What Assia has filed on are specific crystalline forms and salts of that molecule and methods to make them. That's manufacturing and formulation IP, not the right to sell the drug.

Teva can't market brilaroxazine, in any form, while Reviva's molecule patent stands, and that patent runs to 2030, likely ~2035 with the extension that comes with approval. The drug is also unapproved, so there's nothing to genericize. Any Teva version would first need its own trials and FDA approval.

That's why I don't think the PTAB outcome is critical either way:

Granted, if the form in Teva's application is the same one Reviva now wants to patent out to 2046, losing at the PTAB may complicate that extension, though it still wouldn't touch the original drug or the existing trial data.

The proceeding reads as Reviva policing who invented what, which is par for the course once a molecule starts attracting outside IP, not a fight Reviva has to win to survive.

So what exactly is Teva doing?

The skeptical read is that Assia runs this playbook on dozens of third-party molecules to build manufacturing knowledge and optionality, and Teva bought only 1 of the 18 companies behind them.

The other read is that Teva committed scientific and IP capital to this specific molecule while its Phase 3 was still running, kept filing across three continents afterward, and is behaving like a company preparing to be brilaroxazine's manufacturer, partner, or owner.

DTM lists the same possible endgames, meaning manufacturing, supply, licensing, partnership, or occasionally an acquisition.

Then there's what Teva paid the one time it bought one of the 18.

Emalex got $700M upfront for ecopipam, a Phase 3 CNS drug for Tourette syndrome in children, a market measured in the low single-digit billions. Brilaroxazine's lead market is $10B+ today and headed toward $15.9B by 2035, per the IMARC forecast Reviva cites, with bipolar, depression, and ADHD potentially stacked behind it.

For scale, that one deal was ~117x Reviva's $6.0M market cap ($700M upfront / $6.0M), and still north of 50x if you count every $1.50 warrant as a share (~$12M diluted, so ~57x).